Tramadol Reformulations Highlight Pain Challenges and Opportunities

While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.